-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $11

Benzinga·03/12/2026 12:24:57
Listen to the news
Chardan Capital analyst Daniil Gataulin maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $9 to $11.